Methods of treating a tumor using an anti-PD-1 antibody
US12227576B2 · kind B2 · utility
0Cited by
31References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2023 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Jan 30, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.